aHIF: A natural antisense transcript overexpressed in human renal cancer and during hypoxia

Journal of the National Cancer Institute

Volumn 91, Issue 2, 1999, Pages 143-151

  Thrash Bingham, Catherine A ^a   Tartof, Kenneth D ^b,c  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; DISEASE ASSOCIATION; DNA SEQUENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CANCER; LYMPHOCYTE ACTIVATION; NUCLEIC ACID PROBE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VON HIPPEL LINDAU DISEASE;

EID: 0033585496     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.2.143     Document Type: Article

References (56)

1. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998;201(Pt 8):1153-62.
2. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
3. Huang LE, Arany Z, Liningston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996;271:32253-9.
4. Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 1996;271:15117-23.
5. Gradin D, McGuire J, Wenger RH, Kvietikova I, Whitelaw M, Toftgard R, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996;16:5221-31.
6. Wenger RH, Kvietikova I, Rolfs A, Gassmann M, Marti HH. Hypoxia-inducible factor-1α is regulated at the post-mRNA level. Kidney Int 1997; 51:560-3.
7. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood 1991;77:271-7.
8. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci U S A 1991;88:5680-4.
9. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40.
10. Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-β chain gene in human endothelial cells. J Clin Invest 1990;86:670-4.
11. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-9.
12. Eben BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem 1995;270:29083-9.
13. Melillo G, Musso T, Sica A, Taylor LS, Cox GW and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-93.
14. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994;91:6496-500.
15. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 1995;270:21021-7.
16. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757-63.
17. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-77.
18. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 1998;392:405-8.
19. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inductible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
20. Kovacs G. Advances in cancer research. In: Vande Woude GF, Klein G, editors. San Diego (CA): Academic Press, Inc.; 1993. p. 89-124.
21. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Latif F, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
22. Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995;151:561-6.
23. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
24. Herman JG, Latif R, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
25. Duan DR, Pause R, Burgess WH, Aso T, Chen DY, Garett KP, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
26. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997;94:2156-61.
27. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-94.
28. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE, Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995;55:6189-95.
29. Thrash-Bingham CA, Greenberg RE, Howard S, Bruzel A, Bremer M, Goll A, et al. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A 1995;92:2854-8.
30. Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A. Transcription of the dystrophin gene in human muscle and non-muscle tissues. Nature 1998; 333:858-60.
31. Wiesner RJ. Direct quantification of picomolar concentrations of mRNAs by mathematical analysis of a reverse transcription/exponential polymerase chain reaction assay. Nucleic Acids Res 1992;20:5863-4.
32. Santagati S, Gamier M, Carlo P, Violani E, Picotti GB, Maggi A. Quantitation of low abundance mRNAs in glial cells using different polymerase chain reaction (PCR)-based methods. Brain Res Protoc 1997;1:217-23.
33. Sokal RR, Rohlf FJ, Biometry. San Francisco (CA): W. H. Freeman and Co.; 1981.
34. Rohlf FJ, Sokal RR. The statistical tables. San Francisco (CA): W. H. Freeman and Co.; 1981.
35. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-71.
36. Chang Y, Spicer DB, Sonenshein GE. Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line. Oncogene 1991;6:1979-82.
37. Farrell CM, Lukens LN. Naturally occurring antisense transcripts are present in chick embryo chondrocytes simultaneously with the down-regulation of the α1 (I) collagen gene. J Biol Chem 1995;270:3400-8.
38. Malik KT, Wallace JI, Ivins SM, Brown KW. Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation. Oncogene 1995;11:1589-95.
39. Hastings ML, Milcarek C, Martincic K, Peterson ML, Munroe SH. Expression of the thyroid hormone receptor gene, erbAα, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. Nucleic Acids Res 1997;25:4296-300.
40. Kumar M, Carmichael GG. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci U S A 1997;94:3542-7.
41. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
42. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
43. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998;273:1-4.
44. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
45. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
46. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
47. Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988;55:1089-98.
48. Melcher T, Maas S, Herb A, Sprengel R, Higuchi M, Seeburg PH. RED2, a brain-specific member of the ma-specific adenosine deaminase family. J Biol Chem 1996;271:31795-8.
49. Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M. A mammalian RNA editing enzyme. Nature 1996;379:460-4.
50. Proud CG. PKR: a new name and new roles. Trends Biochem Sci 1995; 20:241-6.
51. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF, Silverman RH. Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J Biol Chem 1994;269:14153-8.
52. Scadden AD, Smith CW. A ribonuclease specific for inosine-containing RNA: a potential role in antiviral defence? EMBO J 1997;16: 2140-9.
53. Wenger RH, Rolfs A, Marti HH, Guenet JL, Gassmann M. Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1α. Biochem Biophys Res Comm 1996;223:54-9.
54. Duret L, Dorkeld F, Gautier C. Strong conservation of non-coding sequences during vertebrates evolution: potential involvement in post-transcriptional regulation of gene expression. Nucleic Acids Res 1993;21:2315-22.
55. Makalowski W, Zhang J, Boguski MS. Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res 1996;6:846-57.
56. Lipman DJ. Making (anti)sense of non-coding sequence conservation. Nuc Acids Res 1997;25:3580-3.